Sanofi - ADR (SNY): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNY Price/Volume Stats
| Current price | $52.51 | 52-week high | $57.82 |
| Prev. close | $52.59 | 52-week low | $36.91 |
| Day low | $52.48 | Volume | 1,268,600 |
| Day high | $53.17 | Avg. volume | 1,911,456 |
| 50-day MA | $54.15 | Dividend yield | 2.4% |
| 200-day MA | $46.89 | Market Cap | 132.43B |
SNY Stock Price Chart Interactive Chart >
SNY POWR Grades
- SNY scores best on the Value dimension, with a Value rank ahead of 93.8% of US stocks.
- SNY's strongest trending metric is Quality; it's been moving up over the last 179 days.
- SNY's current lowest rank is in the Momentum metric (where it is better than 17% of US stocks).
SNY Stock Summary
- SNY has a market capitalization of $136,094,608,912 -- more than approximately 98.64% of US stocks.
- Of note is the ratio of SANOFI's sales and general administrative expense to its total operating expenses; 27.08% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of -20.04%, SANOFI's debt growth rate surpasses just 16.12% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to SANOFI are BMY, RTX, DE, SAP, and IBM.
- Visit SNY's SEC page to see the company's official filings. To visit the company's web site, go to www.sanofi.com.
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
Latest SNY News From Around the Web
Below are the latest news stories about SANOFI that investors may wish to consider to help them evaluate SNY as an investment opportunity.
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, SustainedRegeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented results from a Phase 3 study of Dupixent (dupilumab) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. Dupixent demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo, meeting the primary endpoint. Dupixent significantly improved lung |
2 Bear Market Defying Stocks to Buy in MayThis group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35. |
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of MedicineDupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placeboDupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 w |
Sobi's hemophilia A therapy gets review in EUThe European Medicines Agency (EMA) has accepted and validated Swedish Orphan Biovitrum's (Sobi) (OTCPK:BIOVF) application seeking approval of hemophilia A therapy efanesoctocog alfa. Sobi and Sanofi (NASDAQ:SNY) have a collaboration for efanesoctocog alfa, which was approved under the name A... |
5 Things to Know Before Markets OpenPresident Biden said he was confident that negotiators would reach a deal on the debt ceiling and Fed Chair Jerome Powell is set to speak on monetary policy. Here’s what investors need to know today. |
SNY Price Returns
| 1-mo | -2.12% |
| 3-mo | 12.08% |
| 6-mo | 15.79% |
| 1-year | -4.79% |
| 3-year | 12.44% |
| 5-year | 56.87% |
| YTD | 8.42% |
| 2022 | -1.00% |
| 2021 | 5.87% |
| 2020 | -0.83% |
| 2019 | 23.73% |
| 2018 | 4.20% |
SNY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching SNY
Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...